The allogeneic cell therapy market size was estimated at US$ 255.64 million in 2022 it is predicted to grow at a CAGR of 27.44% from 2023 to 2032 to reach around US$ 2,888.59 million by the end of 2032.
The allogeneic cell therapy market report offers an exclusive study of the present state expected at the market dynamics, opportunities, market scheme, growth analysis and regional outlook. The report presents energetic visions to conclude and study the market size, market aspiration, and competitive environment. The research also focuses on the important achievements of the market, research & development, and regional (country by country) growth of the leading vendors operating in the market
The study offers intricate dynamics about different aspects of the global allogeneic cell therapy market, which aids companies operating in the market in making strategies development decisions. The study also elaborates on remarkable changes that are highly anticipated to configure growth of the global allogeneic cell therapy market during the forecast period. It also includes a key indicator analysis that highlights growth prospects of this market and approximate statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.visionresearchreports.com/report/sample/40127
Report Scope of the Allogeneic Cell Therapy Market
| Report Coverage | Details |
| Market Size in 2022 | USD 255.64 million |
| Revenue Forecast by 2032 | USD 2,888.59 million |
| Growth rate from 2023 to 2032 | CAGR of 27.44% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | SSM Cardinal Glennon Children’s Medical Center; Cleveland Cord Blood Center; Duke University School of Medicine; New York Blood Center; Clinimmune Labs; University of Colorado Cord Blood Bank; MD Anderson Cord Blood Bank; LifeSouth Community Blood Centers, Inc.; Bloodworks Northwest; JCR Pharmaceuticals Co., Ltd.; Sumitomo Pharma Co., Ltd.; Atara Biotherapeutics; Mallinckrodt Pharmaceuticals; Tego Science Inc; Takeda Pharmaceutical Company Limited; STEMPEUTICS RESEARCH PVT LTD; Biosolution Co., Ltd.; MEDIPOST Co., Ltd. |
This study covers an elaborate segmentation of the global allogeneic cell therapy market, along with important information and a competition outlook. The report mentions company profiles of players that are currently influence the global allogeneic cell therapy market, wherein various developments, expansions, and winning strategies practiced and execute by leading players have been presented in detail.
Market Segmentation
By Therapy Type
- Stem Cell Therapies
- Hematopoietic Stem Cell Therapies
- Mesenchymal Stem Cell Therapies
- Non-stem Cell Therapies
- Keratinocytes & Fibroblast-based Therapies
- Others
By Therapeutic Area
- Hematological Disorders
- Dermatological Disorders
- Others
Research Methodology
The research methodology acquire by analysts for assemble the global allogeneic cell therapy market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts study numerous annual report declaration, white papers, market association declaration, and company websites to obtain the necessary understanding of the global allogeneic cell therapy market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Allogeneic Cell Therapy Market
5.1. COVID-19 Landscape: Allogeneic Cell Therapy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Allogeneic Cell Therapy Market, By Therapy Type
8.1. Allogeneic Cell Therapy Market, by Therapy Type, 2023-2032
8.1.1. Stem Cell Therapies
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Non-stem Cell Therapies
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Allogeneic Cell Therapy Market, By Therapeutic Area
9.1. Allogeneic Cell Therapy Market, by Therapeutic Area, 2023-2032
9.1.1. Hematological Disorders
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Dermatological Disorders
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Allogeneic Cell Therapy Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.1.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.2.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)
10.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
Chapter 11. Company Profiles
11.1. SSM Cardinal Glennon Children’s Medical Center
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Cleveland Cord Blood Cente
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Duke University School of Medicine
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. New York Blood Center
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Clinimmune Labs
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. University of Colorado Cord Blood Bank
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. MD Anderson Cord Blood Bank
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. LifeSouth Community Blood Centers, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Bloodworks Northwest
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. JCR Pharmaceuticals Co., Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Vision Research Reports
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168